Tech Company Financing Transactions
Inherent Biosciences Funding Round
Inherent Biosciences closed a Series A funding round on 9/7/2022. Investors included Propel Bio Partners, Alliance of Angels and Portfolia.
Transaction Overview
Company Name
Announced On
9/7/2022
Transaction Type
Amount
Unknown
Round
Series A
Investors
Proceeds Purpose
The funding will enable Inherent to expand its pipeline, scale commercial operations and generate the further seminal data necessary to add SpermQT to the standard of care.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2725 East Parleys Way 100
Salt Lake City, UT 84109
USA
Salt Lake City, UT 84109
USA
Phone
Undisclosed
Website
Email Address
Overview
Inherent Biosciences is a molecular diagnostics company at the intersection of epigenetics and AI. Our vision is to revolutionize trial and error medicine and restore hope.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Andy Olson
Chief Operating Officer
Lorry Schneider
Chief Scientific Officer
Kristin Brogaard
Browse more venture capital transactions:
Prev: 9/7/2022: GoodNews venture capital transaction
Next: 9/7/2022: Smobler Studios venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs